Department of Cell Biology, Emory University School of Medicine, Atlanta GA 30322, USA.
Department of Cell Biology, Emory University School of Medicine, Atlanta GA 30322, USA.
Neurotherapeutics. 2024 Oct;21(6):e00462. doi: 10.1016/j.neurot.2024.e00462. Epub 2024 Oct 11.
Recent experimental and clinical data demonstrate a significant dysregulation of the gut microbiome in individuals with Parkinson's disease (PD). With an immense influence on all aspects of physiology, this dysregulation has potential to directly or indirectly contribute to disease pathology. Experimental models have bridged these associations toward defined contributions, identifying various microbiome-dependent impacts to PD pathology. These studies have laid the foundation for human translation, examining whether certain members of the microbiome and/or whole restoration of the gut microbiome community can provide therapeutic benefit for people living with PD. Here, we review recent and ongoing clinically-focused studies that use microbiome-targeted therapies to limit the severity and progression of PD. Fecal microbiome transplants, prebiotic interventions, and probiotic supplementation are each emerging as viable methodologies to augment the gut microbiome and potentially limit PD symptoms. While still early, the data in the field to date support continued cross-talk between experimental systems and human studies to identify key microbial factors that contribute to PD pathologies.
最近的实验和临床数据表明，帕金森病（PD）患者的肠道微生物组存在明显失调。肠道微生物组对生理的各个方面都有巨大影响，这种失调有可能直接或间接地导致疾病的病理过程。实验模型已经将这些关联联系起来，确定了微生物组对 PD 病理的各种影响。这些研究为人类的转化奠定了基础，考察了微生物组中的某些成员和/或整个肠道微生物组群落的恢复是否可以为 PD 患者提供治疗益处。在这里，我们回顾了最近和正在进行的以微生物组为目标的治疗临床重点研究，这些研究旨在限制 PD 的严重程度和进展。粪便微生物组移植、益生元干预和益生菌补充都作为增强肠道微生物组并可能限制 PD 症状的可行方法而出现。虽然还处于早期阶段，但迄今为止该领域的数据支持继续在实验系统和人类研究之间进行交叉对话，以确定导致 PD 病理的关键微生物因素。
